WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Edex Live | April 09, 2020
Just three months after the outbreak of the coronavirus pandemic, several biotech companies in the United States have ramped up their efforts to fight the disease with accelerated schedules for creating new vaccines and beginning clinical trials for potential treatments. In normal circumstances, vaccine development would take around 10 years. But the pharmaceutical industry is racing to compress this timeline with the support of non-profit organisations, government agencies and regulatory author...
MEDTECH, INDUSTRIAL IMPACT
Arcutis Biotherapeutics, Inc. | December 20, 2022
Arcutis Biotherapeutics, Inc. an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced the submission of a supplemental new drug application to the U.S. Food and Drug Administration for the expanded indication of ZORYVE cream 0.3% for the treatment of plaque psoriasis in children ages 2 to 11. As with adults and adolescents, plaque psoriasis is the most common form of psoriasis in children 2 to 11 years of age, with very si...
Bio-Techne Corporation | April 13, 2022
Bio-Techne Corporation launched 3G assay for automated process impurity assessment on the EllaTM immunoassay platform ( NASDAQ: TECH ) and Cygnus Technologies, a division of Maravai LifeSciences ( NASDAQ: MRVI ).
In cell and gene therapy applications, the purification of viral particles to reduce host cell protein (HCP) contamination is an important part of the viral production workflow. To guarantee HCP impurity clearance is performed in compliance with regulatory criteria, accurate quan...
BioLineRx | October 30, 2020
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a planned interim analysis of the ongoing GENESIS Phase 3 trial of motixafortide for stem cell mobilization (SCM) in multiple myeloma patients. At a meeting of the study's independent Data Monitoring Committee (DMC), a planned interim analysis of the study's primary endpoint was conducted independently by the DMC. Based on the statistically sig...
CELL AND GENE THERAPY
CELL AND GENE THERAPY, INDUSTRIAL IMPACT
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE